Complete FDA and NHTSA recall records dated in 2025, organized for browsing by month, category and recalling company.
Select a month to review the recall records reported during that period.
Records are ordered by the best available source date.
Microbial contamination of non-sterile products: tablets may exhibit black spots due to microbial contamination.
Presence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsule
Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was…
Failed Tablet/Capsule specifications; a product complaint was reported for burnt or melted capsules. This was determined to be a result of oxidation by leakage of capsule contents.
Ford Motor Company (Ford) is recalling certain 2025 F-150 trucks. Contact with the engine coolant hose may chafe the engine wire harness or cause a pull out of the Powertrain Control Module…
Ford Motor Company (Ford) is recalling certain 2025 Transit, F-150, and Explorer vehicles. The connecting rod and rod bearing components may have manufacturing defects that can lead to…
Honda (American Honda Motor Co.) is recalling certain 2021-2025 Acura TLX, 2023-2025 Acura MDX, and 2023-2025 Honda Pilot vehicles. The brake pedal pivot pin was not secured properly, which…
Defective Container: This recall is being initiated due to a leaking unit stored horizontally.
Subpotent product: Product has cloudy appearance and tested below assay label claim for 70% Ethyl Alcohol
CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.
Marketed without approved NDA/ANDA: The product has been found to be tainted with Sildenafil and Propoxyphenylsildenafil (a sildenafil analogue).
CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
OOS results reported for the Dissolution (by UV) test.
CGMP Deviations
Lack of Assurance of Sterility: The affected product may exhibit an open seal on the packaging of the applicator.
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
This archive groups records by their reported or recall date. It does not imply that every recall was initiated, announced and resolved during the same calendar year. Open the individual record for the exact dates and source details supplied by FDA or NHTSA.
